1. Home
  2. Labeler Index
  3. Golden State Medical Supply, Inc.
  4. 51407-445
  5. Product Images: Prasugrel

Product Images Prasugrel

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. 51407-444-30LB.jpg - 51407 444 30LB
  2. 51407-445-30LB.jpg - 51407 445 30LB
  3. Figure 1: Non-CABG-Related TIMI Major or Minor Bleeding Events. - image 01
  4. Prasugrel Hydrochloride Structural Formula - image 02
  5. Figure 2: Inhibition (Mean ± SD) of 20 μM ADP-induced Platelet Aggregation (IPA) Measured by Light Transmission Aggregometry after Prasugrel 60 mg. - image 03
  6. Figure 3: Time to first event of CV death, MI, or stroke (TRITON-TIMI 38). - image 04
  7. Figure 4: Subgroup analyses for time to first event of CV death, MI, or stroke (HR and 95% CI; TRITON-TIMI 38) – UA/NSTEMI Patients. - image 05
  8. Figure 5: Subgroup analyses for time to first event of CV death, MI, or stroke (HR and 95% CI; TRITON-TIMI 38) – STEMI Patients. - image 06

Product Label Images

The following 8 images provide visual information about the product associated with Prasugrel NDC 51407-445 by Golden State Medical Supply, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

51407-444-30LB.jpg - 51407 444 30LB

51407-444-30LB.jpg - 51407 444 30LB

51407-445-30LB.jpg - 51407 445 30LB

51407-445-30LB.jpg - 51407 445 30LB

This is a medication label for Prasugrel. Each film-coated tablet contains 10 mg Prasugrel hydrochloride. It is advised to keep this and all medication out of reach of children, protect from moisture, keep and dispense only in the original container, and do not remove desiccant from bottles. The pharmacist should dispense the accompanying medication guide to each patient. Do not use the medication if the inner seal is missing or broken.*

Figure 1: Non-CABG-Related TIMI Major or Minor Bleeding Events. - image 01

Figure 1: Non-CABG-Related TIMI Major or Minor Bleeding Events. - image 01

Prasugrel Hydrochloride Structural Formula - image 02

Prasugrel Hydrochloride Structural Formula - image 02

Figure 2: Inhibition (Mean ± SD) of 20 μM ADP-induced Platelet Aggregation (IPA) Measured by Light Transmission Aggregometry after Prasugrel 60 mg. - image 03

Figure 2: Inhibition (Mean ± SD) of 20 μM ADP-induced Platelet Aggregation (IPA) Measured by Light Transmission Aggregometry after Prasugrel 60 mg. - image 03

Figure 3: Time to first event of CV death, MI, or stroke (TRITON-TIMI 38). - image 04

Figure 3: Time to first event of CV death, MI, or stroke (TRITON-TIMI 38). - image 04

This appears to be a chart or graph showing the percentage of cardiovascular death, nonfatal stroke, and nonfatal M (which is unclear what it stands for) over time (measured in days) after using something called Prasugrel Tobets in patients with UANSTEMI. The chart shows a statistically significant result with a p-value of 0.002.*

Figure 4: Subgroup analyses for time to first event of CV death, MI, or stroke (HR and 95% CI; TRITON-TIMI 38) – UA/NSTEMI Patients. - image 05

Figure 4: Subgroup analyses for time to first event of CV death, MI, or stroke (HR and 95% CI; TRITON-TIMI 38) – UA/NSTEMI Patients. - image 05

Figure 5: Subgroup analyses for time to first event of CV death, MI, or stroke (HR and 95% CI; TRITON-TIMI 38) – STEMI Patients. - image 06

Figure 5: Subgroup analyses for time to first event of CV death, MI, or stroke (HR and 95% CI; TRITON-TIMI 38) – STEMI Patients. - image 06

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.